(IHE) U.S. Pharmaceuticals - Overview
Etf: Pharmaceutical, Biotech, Vaccine, Generic, OTC
Dividends
| Dividend Yield | 2.02% |
| Yield on Cost 5y | 2.65% |
| Yield CAGR 5y | -15.81% |
| Payout Consistency | 92.7% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 22.8% |
| Relative Tail Risk | 0.89% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.23 |
| Alpha | 20.85 |
| Character TTM | |
|---|---|
| Beta | 0.526 |
| Beta Downside | 0.592 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.92% |
| CAGR/Max DD | 1.00 |
Description: IHE U.S. Pharmaceuticals December 26, 2025
The iShares U.S. Pharmaceuticals ETF (NYSE ARCA:IHE) tracks an index of U.S. companies that develop, manufacture, or distribute prescription drugs, over-the-counter medicines, or vaccines.
By design, the fund allocates at least 80% of its net assets to the underlying index constituents and may use up to 20% for futures, options, swaps, cash, or cash equivalents, which introduces modest tactical flexibility but also concentration risk; the ETF is classified as non-diversified under SEC rules.
Key market metrics (as of Q3 2024) include an expense ratio of 0.43%, a weighted-average market cap of roughly $85 billion, and top holdings such as Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK), together representing about 30% of assets. The sector’s growth drivers are an aging U.S. population (projected to increase Medicare drug spending by ~4% annually), robust R&D pipelines targeting oncology and gene-therapy, and a modest rebound in pricing power after recent policy uncertainty around drug price negotiations.
For a deeper quantitative breakdown, you might explore ValueRay’s analytics platform to assess risk-adjusted returns and sector exposure.
What is the price of IHE shares?
Over the past week, the price has changed by +4.25%, over one month by +6.80%, over three months by +18.95% and over the past year by +30.98%.
Is IHE a buy, sell or hold?
What are the forecasts/targets for the IHE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 104.8 | 16% |
IHE Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 975.4m USD (975.4m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 975.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 975.4m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.85% (E(975.4m)/V(975.4m) * Re(7.85%) + (debt-free company))
Discount Rate = 7.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)